Over the past decade, the number of clinical trials using a biosimilar treatment has been on the rise. GlobalData extracted all biosimilar drug trials up to December 21, 2018 and then broke them down by therapy area.

The largest number of biosimilar clinical trials took place in oncology, followed by immunology, hematological disorders, metabolic disorders, and musculoskeletal.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

When split into phases GlobalData found biosimilar trials were most numerous in Phase I and Phase III across the major therapy areas (Figure 1). Musculoskeletal had the largest number of Phase I trials and a much higher number of Phase IV trials than any other therapy area. One of the largest treatment areas for approved biologic drugs is arthritis, so this may explain why there are so many post-marketing trials in this therapy area.